Clinical Trials

MASTER-II
  • MGuard PrimeTM
  • PI: Gregg Stone; Co-PI: Jose Henriques
  • STEMI patients
  • Randomized study of MGuard PrimeTM vs. BMS/DES
  • Co-Primary endpoint: ST-segment resolution within 60-90 minutes of procedure AND composite of all-cause death or recurrent TV re-MI at 365 days post-procedure.
  • Follow-up*

            *  Enrollment discontinued

iMOS Prime
  • MGuard PrimeTM
  • PI: Giovanni Amoroso
  • 97 patients
  • STEMI
  • Observational registry with 12 months clinical FU
  • 6 month follow-up completed
  • Follow-up on-going 
MASTER
  • MGuardTM
  • Chairman: Gregg Stone, PIs: Dariusz Dudek; Alexandre Abizaid; Sigmund Silber
  • 432 patients
  • Randomized study of MGuardTM vs. BMS/DES; with 12 months clinical FU
  • Completed
MAGICAL
  • MGuardTM
  • PI: Dariusz Dudek
  • 60 patients
  • STEMI
  • Blush, ST resolution, TIMI, 6M clinical FU
  • Completed
FIM
  • MGuardTM
  • PI: Ebrehard Grube
  • 41 patients
  • Native, SVG (stable angina)
  • 6M angiographic FU, 12M Clinical
  • Completed